Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MaaT033 capsule
MaaT033 · 1 trial · 1 indication
Percentage of patients who have not shown disease progression regarding complete response, partial response, stable disease as per RECIST 1.1 criteria. Confirmation of response must be demonstrated with an assessment 4-8 weeks from the initial response assessment.
| Arm | Type | Description |
|---|---|---|
| Combination of MaaT033 + Cemiplimab (CB) | EXPERIMENTAL | CB will be administered every 3 weeks. Oral pooled fecal microbiotherapy MaaT033 will be taken by patient (capsules) for a week before CB administration, repeated every other 3 weeks for 6 months. |
| Best Investigator's Choice (BIC) | ACTIVE_COMPARATOR | Patients will receive chemotherapy according to current standard of care protocols according to investigator's best choice from current guidelines combinations. |
| Name | Type | Description |
|---|---|---|
| MaaT033 capsule | DRUG | MaaT033 capsule will be taken orally once a day for a week before every Cemiplimab cycle for the first 6 months of treatment. |
| Cemiplimab | DRUG | CB will be administered 350 mg IV over 30 minutes every 21 days up to 2 years |
| Cisplatin | DRUG | 75mg/m2 at day 1 (d1) every 21 days (q21) |
| Carboplatine | DRUG | Area Under the Curve (AUC) 5-6 at d1 q21 |
| Pemetrexed (Alimta) | DRUG | 500mg/m2 at day 1 (d1) q21 |
| Bevacizumab | DRUG | 10mg/kg at d1 and day 15 (d15) every 28 days (q28) |
| Paclitaxel | DRUG | 175mg/m2 at d1 q21 or 80 mg/m2 at d1, day 8 (d8), day 15 q28 |
| gemcitabine | DRUG | 1250 or 1000 mg/m2 d1, d8 q21 |
| Docetaxel | DRUG | 75 mg/m2 d1 q21 or 33mg/mq d1, d8 q21 q21 |
| Vinorelbine i.v. 25 mg/m² | DRUG | 25-30 mg/m2 d1, d8 q21 |
| Vinorelbine oral | DRUG | 30 mg/50 mg per os 3 days per week (metronomic) |
Inclusion Criteria: 1. Participants who are at least 18 years of age on the day of signing informed consent, 2. All participants must understand spoken and written national language, 3. Histologically confirmed diagnosis of NSCLC (adenocarcinoma versus squamous cell carcinoma versus others) 4. Have...
MaaT033 is an investigational oral pooled fecal microbiotherapy being studied in advanced non-small cell lung cancer (NSCLC). It is being evaluated in patients with resistance to treatment due to antibiotic uptake, given concomitantly with cemiplimab versus best investigator's choice. The drug is in Phase 2 clinical development.
MaaT033 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. The drug is currently in Phase 2 clinical development for advanced non-small cell lung cancer.
MaaT033 is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. It is being studied in a Phase 2 trial for advanced non-small cell lung cancer in patients with resistance to treatment due to antibiotic uptake.
MaaT033 is being studied in one active Phase 2 clinical trial, NCT07001618. This randomized, active-controlled trial enrolls 162 patients in France with advanced non-small cell lung cancer. The trial is recruiting participants aged 18 years and older.
Yes, MaaT033 is also known as MaaT033 capsule. It is an oral pooled fecal microbiotherapy being developed by Regeneron Pharmaceuticals for advanced non-small cell lung cancer. The drug is currently in Phase 2 clinical development.